Novartis' Gorsky to return to J&J

Well, we didn't have to watch Alex Gorsky (photo) for long. According to the Wall Street Journal, when Novartis said that the U.S. pharma CEO was leaving, they left out the part about his returning to alma mater Johnson & Johnson. Gorsky will be chairman of Ethicon, a J&J unit that makes surgical equipment and sutures. Gorsky left J&J to join Novartis in 2004.

Novartis also told the WSJ that Gorsky's exit had nothing to do with any of the changes new worldwide pharma chief Joe Jiminez is making at the company.

- check out the story in the Wall Street Journal

Suggested Articles

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.

Hengrui's Sun Piaoyang is stepping down as chairman, but he'll retain control of the pharma major he's headed for 30 years—and made a fortune…

Astellas tapped Adaptimmune to develop T-cell therapies. Ireland hit Takeda with an unexpected Shire tax bill. PD-1 med Tyvyt hit its goal in NSCLC.